A hemp industry’s lawsuit, challenging DEA’s position on CBD, picks up support of 28 US legislators. Check out in this post from The Cannabist how DEA’s stance on CBD extracts is cause for confusion. A bipartisan congressional coalition pushed back on the U.S. Drug Enforcement Administration’s assertion that cannabidiol and extracts derived from hemp are Schedule I ... Continue Reading